BERGEN, Norway, May 18, 2018 /PRNewswire/ --
BerGenBio ASA (OSE: BGBIO) announces that the company and its
collaborators will present interim clinical data from its Phase II
clinical development programme with bemcentinib, a selective, oral
AXL inhibitor, in acute myeloid leukaemia (AML) and myeloid
dysplastic syndrome (MDS) at the 23rd Congress of the European
Hematology Association (EHA) in Stockholm (14-17 June
2018).
Abstracts are now available online at https://ehaweb.org and
details of the presentations are below. The posters presented at
EHA will be made available on www.bergenbio.com in the Investors /
Presentations section following the sessions.
Presentations at EHA
Saturday 16 June, 5:30 - 7:00 PM
CEST
Ph II trial with selective oral AXL inhibitor bemcentinib
(BGB324) in relapsed/refractory AML and MDS: Identification of
predictive and pharmacodynamic biomarker candidates associated with
pt benefit
- Sonja Loges, MD, PhD et
al
- Session: Acute myeloid leukemia - Clinical
- Abstract code: PS981
Single cell signaling pharmacodynamics and clonal evolution in a
phase I/II clinical trial of selective AXL inhibitor bemcentinib
(BGB324) in R/R acute myeloid leukemia and myelodysplastic
syndrome
- Monica Hellesøy, PhD et al
- Session: Acute myeloid leukemia - Biology & Translational
Research
- Abstract code: PS965
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company
focused on developing a pipeline of first-in-class AXL kinase
inhibitors as a potential cornerstone of combination cancer
therapy. The Company is a world leader in understanding the
essential role of AXL kinase in mediating cancer spread, immune
evasion and drug resistance in multiple aggressive solid and
haematological cancers.
BerGenBio's lead product, bemcentinib (BGB324), is a selective,
potent and orally bio-available small molecule AXL inhibitor in
four Company sponsored Phase II clinical trials in major cancer
indications, with read-outs anticipated during 2018. It is the only
selective AXL inhibitor in clinical development.
The Company sponsored clinical trials are:
- Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation
driven non-small cell lung cancer (NSCLC)
- Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the
lung, and
- Bemcentinib with KEYTRUDA in triple-negative breast cancer
(TNBC).
- Bemcentinib as a single agent and combination therapy in acute
myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS)
The clinical trials combining bemcentinib with KEYTRUDA in
adenocarcinoma of the lung and TNBC are conducted in collaboration
with Merck & Co., Inc. (Kenilworth,
NJ, USA), through a subsidiary.
In addition, a number of investigator-sponsored trials are
underway, including a trial to investigate bemcentinib with either
MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in
advanced melanoma, as well as a trial combining bemcentinib with
docetaxel in advanced NSCLC.
BerGenBio is simultaneously developing a companion diagnostic
test to identify patient subpopulations most likely to benefit from
treatment with bemcentinib. This will facilitate more efficient
registration trials and support a precision medicine based
commercialization strategy.
The Company is also developing a diversified pre-clinical
pipeline of drug candidates, including BGB149, an anti-AXL
monoclonal antibody.
For further information, please visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered
trademark of OSI Pharmaceuticals, LLC., marketed by
Roche-Genentech. TAFLINAR® is a registered trademark of Novartis
International AG and MEKINIST® is a registered trademark of GSK
plc.
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47-917-86-304
Rune Skeie, CFO, BerGenBio
ASA
rune.skeie@bergenbio.com
+47-917-86-513
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47-995-13-891
International Media Relations
David Dible, Mark Swallow, Marine
Perrier, Citigate Dewe Rogerson
bergenbio@citigatedewerogerson.com
+44-207-638-9571
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/bergenbio-asa/r/bergenbio-to-present-interim-clinical-and-biomarker-data-with-selective-axl-inhibitor-bemcentinib-in,c2524214
View original
content:http://www.prnewswire.com/news-releases/bergenbio-to-present-interim-clinical-and-biomarker-data-with-selective-axl-inhibitor-bemcentinib-in-aml-and-mds-at-eha-300650898.html
SOURCE BerGenBio ASA